Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Celyad CAR-T Clinical Trial for Solid Tumors Underway

XTALKS VITALS NEWS

Tumor

To date, the company has recruited two patients with solid tumors, with plans to assess the CAR-T therapy candidate – NKR-2 – in five solid tumors, as well as two hematological cancers.

Share this!

January 18, 2017 | by Sarah Hand, M.Sc.

In an effort to apply CAR-T immunotherapy to treat solid tumors, biotech company Celyad has started to enroll patients in its Phase Ib THINK clinical trial. To date, the company has recruited two patients with solid tumors, with plans to assess the CAR-T therapy candidate – NKR-2 – in five solid tumors, as well as two hematological cancers.

The first and second patients recruited to the clinical trial had colorectal and pancreatic cancer, respectively. Celyad expects to enroll 14 patients per cancer type, including acute myeloid leukemia and multiple myeloma.

“Celyad is now conducting one of the largest clinical trials in the CAR-T space, with a highly disruptive technology,” said Christian Homsy, CEO of Celyad. “The THINK trial is a world first, evaluating CAR-T NKR-2 cells in both hematological and solid tumors. Based on our outstanding of the preclinical data, our confidence in this technology is very high.”



The company expects results from the THINK trial to be available early next year. Compared to Celyad, most other companies in the CAR-T space – including Kite Pharma and Novartis – are focused on applying the immunotherapy to blood cancers.

While CAR-T immunotherapies utilizing the CD19 protein can be highly effective against hematological cancers, they are not as useful when it comes to solid tumor types. Celyad’s NKR-2 takes advantage of the NKG2D protein to help the CAR cells target other cancers.

“Preclinical results as well as first Phase I safety data are very encouraging,” said Prof. Jean-Pascal Machiels, Head of Medical Oncology at Cliniques Universitaires St- Luc (UCL) in Belgium. “We do believe that the THINK study, which is the first to use multiple dosing in patients suffering from very aggressive solid or hematologic metastatic tumors, potentially opens a new avenue for cancer treatment.”

Celyad’s first Phase I clinical trial of their CAR-T candidate was tested in patients with acute myeloid leukemia and multiple myeloma. While one patient in this trial showed no disease progression after the 12-week study period, the THINK trial will use NKR-2 in a higher concentration in order to improve efficacy.


Keywords: CAR-T, Clinical Trial, Solid Tumor


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.